Nora Therapeutics

Nora Therapeutics is a specialty biopharmaceutical company in California that focuses on developing therapeutics to address clinical unmet needs in reproductive medicine. Founded in 2007 in Palo Alto, California, United States by Chris McClain, Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF) procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance.